Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Anthracycline-Resistant Breast Cancer

Treatment of Anthracycline-Resistant Breast Cancer The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6–12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Treatment of Anthracycline-Resistant Breast Cancer

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/treatment-of-anthracycline-resistant-breast-cancer-ErcxAkWoQ2
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00002
Publisher site
See Article on Publisher Site

Abstract

The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6–12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy).

Journal

American Journal of Cancer – Springer Journals

Published: Aug 10, 2012

References

  • Polychemotherapy for early breast cancer: an overview of the randomised trials
  • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
    Levine, M.N.; Bramwell, V.H.; Pritchard, K.I.
  • Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial
  • Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens
    A’Hern, R.P.; Smith, I.E.; Ebbs, S.R.
  • Cytotoxic and hormonal treatment of metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women
    Fossati, R.; Confalonieri, C.; Torri, V.
  • Current options in treatment of anthracycline-resistant breast cancer
    Kroger, N.; Achterrath, W.; Hegewisch-Becker, S.
  • Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
    Cardoso, F.; DiLeo, A.; Lohrisch, C.
  • A unified definition of clinical anthracycline resistant breast cancer
    Pivot, X.; Asmar, L.; Buzdar, A.U.
  • Current options in the treatment of anthracycline-resistant breast cancer
    Kroger, N.; Achterrath, W.; Hegewisch-Becker, S.
  • Phase II trial of Docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline- resistant metastatic breast cancer
    Valero, V.; Holmes, F.A.; Walters, R.S.
  • Phase II trial of Docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
    Ravdin, P.; Burris, H.; Cook, G.
  • Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients
    Alexandre, J.; Bleuzen, P.; Bonneterre, J.
  • Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance
    Ando, M.; Watanabe, T.; Nagata, K.
  • Weekly docetaxel in patients with metastatic breast cancer
    Stemmler, H.J.; Gutschow, K.; Sommer, H.
  • Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
    Perez, E.A.; Vogel, C.L.; Irwin, D.H.
  • High-dose paclitaxel with granulocytes colony stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial
    Vermorken, J.B.; Bokkel Huinink, W.W.; Mandjes, I.A.
  • Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial
    Abrams, J.S.; Vena, D.A.; Baltz, J.
  • Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma
    Ibrahim, N.K.; Rahman, Z.; Valero, V.
  • Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin Breast
    Nieto, Y.; Martin, M.; Alonso, J.L.
  • Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
    Blum, J.L.; Dieras, V.; Russo, P.M.
  • A phase II study of oral eniluracil/ fluorouracil in patients with anthracycline-refractory or anthracycline-and taxane-refractory advanced breast cancer
    Skovsgaard, T.; Davidson, N.G.; Piccart, M.J.
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer
    Rivera, E.; Sutton, L.; Colewell, B.
  • Activity of gemcitabine in metastatic breast cancer patients previously treated with an anthracycline- containing regimens [abstract]
    Spielmann, M.; Kalla, S.; Llombart-Cussac, A.
  • Second and third-line treatment of metastatic breast cancer with gemcitabine [abstract]
    Brodowicz, T.; Moslinger, R.; Herscovic, V.
  • Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both and anthracycline and a taxane
    Smorenberg, C.H.; Bontenbal, M.; Seyunaeve, C.
  • Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study
    Garufi, C.; Nistico, C.; Brienza, S.
  • Multi national study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, M.A.; Vogel, C.L.; Tripathy, D.
  • Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
    O’Shaughnessy, J.; Miles, D.; Vukelja, S.
  • The platinum agents: a role in breast cancer treatment
    Crown, J.P.
  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer
    Tortoriello, A.; Facchini, G.; Caponigro, F.
  • Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a phase I–II study of doxorubicin-treated patients
    Ellis, G.K.; Gralow, J.R.; Pierce, H.I.
  • Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure
    Martin, M.; Lluch, A.; Casado, A.
  • Vinorelbine combined with paclitaxel infused over 96 hours for patients with metastatic breast carcinoma
    Cocconi, G.; Mambrini, A.; Quarta, M.
  • Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
    Andres, R.; Mayordomo, J.; Isla, D.
  • Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines
    Marti, J.L.; Bueso, P.; Mayordomo, J.I.
  • Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of phase II study
    Klaasen, U.; Wilke, H.; Harstrick, A.
  • A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
    Villalona-Calero, M.A.; Blum, J.L.; Jones, S.E.
  • Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines
    Zambetti, M.; Mariani, G.; Demicheli, R.
  • Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer
    Lombardi, D.; Magri, M.D.; Crivellari, D.
  • Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer
    Mariani, G.; Tagliabue, P.; Zucchinelli, P.
  • Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study
    Valenza, R.; Leonardi, V.; Gebbia, V.
  • Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial
    Mavroudis, D.; Malamos, N.; Alexopoulos, A.
  • Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    Ray-Coquard, I.; Biron, P.; Bachelot, T.
  • Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines
    Vassilomanolakis, M.; Koumakis, G.; Barbounis, V.
  • Docetaxel-cisplatin combination chemotherapy in patients with anthracycline-resistant advanced breast cancer
    Spielmann, M.; Llombart, A.; Zeleck, L.
  • Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I–II clinical trial
    Campisis, C.; Fabi, A.; Papaldo, P.
  • Phase I/II trial gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes
    Salman, H.S.; Tanaka, K.; Sparano, J.A.
  • Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
    Nabholtz, J.M.; Gelmon, K.; Bontenbal, M.
  • Randomised, phase II trial comparing oral capecitabine with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
    Talbot, D.C.; Moiseyenko, V.; Bell, S.
  • Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-flurouracil plus leucovorin versus combination of mitoxantrone, 5-flurouruacil plus leucovorin
    Venturino, A.; Comandini, D.; Simoni, C.
  • Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose- finding study
    Frasci, G.; Cornelia, P.; D’Aiuto, G.
  • Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma
    Belpomme, D.; Gauther, S.; Pujade-Laurainem, E.
  • Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
    Dieras, V.; Marty, M.; Tubiana, N.
  • Randomized comparison of vinorelbine and melphalan in anthracycline-refractory breast cancer
    Jones, S.; Winer, E.; Vogel, C.
  • Taxotere versus 5-fluorouracil plus Navelbine as second-line chemotherapy in patients with metastatic breast cancer [abstract 564]
    Bonneterre, J.; Roche, H.; Monnier, A.
  • Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy
    Nabholtz, J.M.; Senn, J.H.; Bezwoda, W.R.
  • Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group
    Sjostrom, J.; Blomqvist, C.; Mouridsen, H.
  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    O’Brien, M.E.; Wigler, N.; Inbar, M.
  • Phase III comparison of taxotere and paclitaxel in patients with metstatic breast cancer (TAX 311)
    Ravdin, P.; Erban, J.; Overmoyer, B.
  • Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline resistant breast cancer
    Leung, P.P.; Tannock, I.F.; Oza, A.M.
  • A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer
    Hutton, J.; Brown, R.; Rorowitz, M.
  • A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine
    Launois, R.; Reboul-Marty, J.; Henry, B.
  • Docetaxel: a pharmacoeconomic review of its use in the treatment of metastatic breast cancer
    Lamb, H.M.; Wiseman, L.R.
  • Palliative effect of chemotherapy: objective response is associated with symptom improvement in patients with metastatic breast cancer
    Geels, P.; Eisenhauer, E.; Bezjak, A.
  • Dose chemotherapy improve survival in advanced breast cancer?: a statistical overview
    A’Hern, R.P.; Ebbs, S.R.; Baum, M.B.
  • Selecting and appraising studies for a systematic review
    Meade, M.O.; Richardson, W.S.